Drug Profile
Human papillomavirus vaccine - Soligenix
Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Soligenix
- Class Cancer vaccines; Papillomavirus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Human papillomavirus infections
Most Recent Events
- 28 Jul 2019 No recent reports of development identified for preclinical development in Human-papillomavirus-infections(Prevention) in USA (Parenteral)
- 02 Jun 2015 Immunogenicity data from a preclinical trial in Human papillomavirus infections (Prevention) released by Soligenix
- 02 Jun 2015 Preclinical trials in Human papillomavirus infections (Prevention) in USA (Parenteral)